Literature DB >> 27599898

Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis.

Y C Lai1, Y W Yew2, W C Lambert1.   

Abstract

Bullous pemphigoid (BP) is a chronic, autoimmune vesiculobullous disease that frequently occurs in the elderly population. Previous epidemiological studies have suggested an association between BP and neurological diseases; some studies, however, showed conflicting results. This study aimed to investigate if patients with BP have significantly higher risks for neurological disorders, compared to controls. A comprehensive search was performed using MEDLINE, EMBASE and Cochrane library databases. Case-control and cohort studies that assessed the relationship between BP and neurological diseases were included. DerSimonian and Laird random-effects models were utilized to calculate the pooled relative risks (RRs). Publication bias was evaluated qualitatively by constructing a funnel plot and quantitatively by conducting Egger's test. Fourteen studies, with 23 369 BP cases and 128 697 controls were included in this meta-analysis. Patients with BP were significantly more likely to have stroke (RR 2.68, 95% CI: 2.07-3.46), Parkinson's disease (PD; RR 3.42, 95% CI: 3.01-3.87), dementia (RR 4.46, 95% CI: 3.23-6.16), epilepsy (RR 2.98, 95% CI: 1.42-6.28), multiple sclerosis (RR 12.40, 95% CI: 6.64-23.17) and any aforementioned neurological disease (RR 4.93, 95% CI: 3.62-6.70), compared to controls. Moderate to high heterogeneity were observed for analyses of most neurological diseases, except for PD and multiple sclerosis. This study provided support for a significant association between BP and neurological diseases. Clinicians should be aware of this association and manage modifiable risk factors for neurological diseases accordingly.
© 2016 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2016        PMID: 27599898     DOI: 10.1111/jdv.13660

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  29 in total

1.  Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study.

Authors:  Khalaf Kridin; Kyle Amber; Mogher Khamaisi; Doron Comaneshter; Erez Batat; Arnon D Cohen
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

2.  Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.

Authors:  Seon Gu Lee; Hee Jung Lee; Moon Soo Yoon; Dong Hyun Kim
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

Review 3.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

4.  Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.

Authors:  Khalaf Kridin; Reuven Bergman
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

Review 5.  Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

Review 6.  Bullous pemphigoid: An immune disorder related to aging (Review).

Authors:  Maria Ludovica Deotto; Alice Spiller; Alvise Sernicola; Mauro Alaibac
Journal:  Exp Ther Med       Date:  2021-11-15       Impact factor: 2.447

7.  Bullous pemphigoid and milia: prevalence and clinical laboratory findings in a Brazilian sample.

Authors:  Sebastián Vernal; Ederson Valei de Oliveira; Roberto Bueno Filho; Tamiris A Julio; Eduardo A Donadi; Aline Turatti; Norito Ishii; Takashi Hashimoto; Ana Maria Roselino
Journal:  An Bras Dermatol       Date:  2022-05-27       Impact factor: 2.113

8.  Biological predictors shared by dementia and bullous pemphigoid patients point out a cross-antigenicity between BP180/BP230 brain and skin isoforms.

Authors:  Tamiris A Julio; Sebastian Vernal; Juliana D Massaro; Matheus C Silva; Eduardo A Donadi; Julio C Moriguti; Ana M Roselino
Journal:  Immunol Res       Date:  2018-10       Impact factor: 2.829

Review 9.  BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.

Authors:  Yale Liu; Liang Li; Yumin Xia
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

10.  Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis.

Authors:  Yi-Di Liu; Yan-Hong Wang; Yi-Cong Ye; Wen-Ling Zhao; Li Li
Journal:  Arch Dermatol Res       Date:  2017-03-19       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.